Hypoglycaemia
Insulinoma
6 questions
Question 1 · Whipple's triad
Correct answer: Whipple's triad: 1) symptoms consistent with hypoglycaemia, 2) blood glucose <3.0 during symptoms, 3) relief with glucose. Suggests insulinoma or other endogenous hypoglycaemia cause
Why
Whipple's triad: symptoms of hypoglycaemia + low measured BG during symptoms + relief with glucose. Endogenous hyperinsulinaemia (insulinoma) presents with fasting hypoglycaemia with high insulin and C-peptide (distinguishes from exogenous insulin injection).
Key point
Whipple's triad: symptoms + low BG + relief with glucose. Fasting hypoglycaemia with high insulin = insulinoma.
Question 2 · Diagnostic test
Correct answer: 72-hour supervised fast with measurement of glucose, insulin, C-peptide, proinsulin, and beta-hydroxybutyrate when symptomatic or glucose <3.0
Why
72-hour supervised fast: gold standard for diagnosing endogenous hyperinsulinaemia. Positive: glucose <3.0 + insulin ≥3 mU/L + C-peptide ≥0.2 nmol/L + proinsulin elevated. Beta-hydroxybutyrate suppressed (insulin suppresses ketosis). 75% of insulinomas detected within 24h. Localise: CT/MRI, EUS; specialist GLP-1R or Ga-68 DOTATATE PET if needed.
Key point
72-hour fast: gold standard. Hypoglycaemia + high insulin + high C-peptide + low BHB = endogenous insulin excess.
Question 3 · Treatment
Correct answer: Surgical enucleation or distal pancreatectomy — curative in >90% of benign insulinomas
Why
Insulinoma treatment: surgery is curative in 90%+ (90% benign).
- Laparoscopic enucleation (small, accessible, benign tumours) or distal pancreatectomy
- Intraoperative USS to find small lesions
- Diazoxide (opens K-ATP channels, inhibits insulin release): medical temporisation before surgery or if inoperable
- Octreotide: only if tumour expresses somatostatin receptors
Key point
Insulinoma: surgery curative >90%. Laparoscopic enucleation. Diazoxide: medical bridge. Octreotide: if somatostatin receptor positive.
Question 4 · Malignant insulinoma
Correct answer: Malignancy defined by metastases (liver most common) — histology alone cannot distinguish. Symptoms persist/worsen. PET/octreoscan for staging
Why
Malignant insulinoma: only defined by evidence of metastasis (histologically benign-appearing tumour can still metastasise). 10% of insulinomas. Liver metastases most common. Management: surgery if resectable. Everolimus (mTOR inhibitor), sunitinib (tyrosine kinase inhibitor) for advanced disease. Octreotide LAR.
Key point
Malignant insulinoma: defined by metastases only (not histology). Everolimus and sunitinib for advanced disease.
Question 5 · MEN1 association
Correct answer: MEN1 (Multiple Endocrine Neoplasia type 1) — parathyroid hyperplasia + pancreatic NET + pituitary adenoma
Why
MEN1: autosomal dominant (menin gene mutation). Classic triad:
- Primary hyperparathyroidism (most common)
- Pancreatic neuroendocrine tumours (gastrinoma, insulinoma, glucagonoma, VIPoma)
- Pituitary adenoma (prolactinoma, GH-secreting)
Insulinoma in MEN1: often multiple. Screen first-degree relatives.
Key point
MEN1: parathyroid + pancreatic NET (insulinoma/gastrinoma) + pituitary adenoma. Menin mutation. Screen family.
Question 6 · Preventing hypoglycaemia
Correct answer: Oral diazoxide (100-600mg daily in divided doses) — inhibits insulin secretion by opening KATP channels. Frequent carbohydrate-containing snacks
Why
Insulinoma pre-operative management: oral diazoxide (100-600mg daily) — opens pancreatic beta cell KATP channels, inhibiting insulin secretion. Side effects: fluid retention (add thiazide), hirsutism. Frequent high-carbohydrate snacks. Continuous glucose monitoring (CGM) to detect nocturnal hypoglycaemia.
Key point
Insulinoma preoperative: diazoxide (opens KATP channels, inhibits insulin) + frequent carbohydrate snacks. CGM monitoring.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.